{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T13:52:46Z","timestamp":1792936366702,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005036","name":"Universitetet i Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Women suffering from severe nausea and vomiting during pregnancy, hyperemesis gravidarum, have poor quality of life and increased risk of potentially fatal maternal and fetal complications. There is increasing and reassuring knowledge about safety of antiemetics in pregnancy. In 2013, the European Medical Agency (EMA) issued a warning on metoclopramide limiting treatment to maximum five days. Metoclopramide was the most used antiemetic in pregnancy at the time the warning was implemented in the Norwegian hyperemesis guidelines (2014). We aimed at describing changes in the treatment of hyperemesis over time, including changes associated with the EMA warning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective chart review of all women hospitalized for hyperemesis gravidarum with metabolic disturbances between 01\/Jan\/2002 and 31\/Dec\/2019 at a university hospital serving nearly 10% of the pregnant population in Norway. Time-series analysis described changes over time and interrupted time series analysis quantified changes in treatment and clinical outcomes related to the EMA warning.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 1,064 women (1.2% of the birthing population) were included. The use of meclizine, prochlorperazine, and ondansetron increased during 2002\u20132019. This led to a yearly increase in the percentage of women using any antiemetic of 1.5% (95%CI 0.6; 2.4) pre-hospital, 0.6% (95%CI 0.2; 1.1) during hospitalization, and 2.6% (95%CI 1.3; 3.8) at discharge. Overall, only 50% of the women received antiemetics pre-hospital. Following the EMA warning, prehospital use of metoclopramide dropped by 30% (95%CI 25; 36), while use of any antiemetic pre-hospital dropped by 20% (95%CI 5.7; 34). In timely association, we observed a decrease in gestational age (-3.8\u00a0days, 98.75%CI 0.6; 7.1) at first admission, as well as indication of increased rate of termination of pregnancy with an absolute increase of 4.8% (98.75%CI 0.9; 8.7) in 2014.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>During 2002\u20132019, the overall use of antiemetics in treatment of hyperemesis increased. The EMA-warning on metoclopramide in 2013 temporarily limited pre-hospital antiemetic provision associated with hospitalization at lower gestational length and indication of an increase in termination of pregnancy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-022-04777-x","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T08:06:48Z","timestamp":1654157208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Antiemetic treatment of hyperemesis gravidarum in 1,064 Norwegian women and the impact of European warning on metoclopramide: a retrospective cohort study 2002\u20132019"],"prefix":"10.1186","volume":"22","author":[{"given":"Hilde","family":"Erdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jone","family":"Trovik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"issue":"2","key":"4777_CR1","first-page":"e171","volume":"20","author":"TR Einarson","year":"2013","unstructured":"Einarson TR, Piwko C, Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J Popul Ther Clin Pharmacol. 2013;20(2):e171\u201383.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"4777_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejogrb.2021.09.004","volume":"266","author":"LAW Jansen","year":"2021","unstructured":"Jansen LAW, Koot MH, Van\u2019t Hooft J, Dean CR, Bossuyt PMM, Ganzevoort W, et al. The windsor definition for hyperemesis gravidarum: A multistakeholder international consensus definition. Eur J Obstet Gynecol Reprod Biol. 2021;266:15\u201322.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"4777_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41572-019-0110-3","volume":"5","author":"MS Fejzo","year":"2019","unstructured":"Fejzo MS, Trovik J, Grooten IJ, Sridharan K, Roseboom TJ, Vikanes A, et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat Rev Dis Primers. 2019;5(1):62.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4777_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/ppe.12416","volume":"32","author":"L Fiaschi","year":"2018","unstructured":"Fiaschi L, Nelson-Piercy C, Gibson J, Szatkowski L, Tata LJ. Adverse Maternal and Birth Outcomes in Women Admitted to Hospital for Hyperemesis Gravidarum: a Population-Based Cohort Study. Paediatr Perinat Epidemiol. 2018;32(1):40\u201351.","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"6","key":"4777_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ajog.2021.03.006","volume":"224","author":"M Nana","year":"2021","unstructured":"Nana M, Tydeman F, Bevan G, Boulding H, Kavanagh K, Dean C, et al. Hyperemesis gravidarum is associated with increased rates of termination of pregnancy and suicidal ideation: results from a survey completed by >5000 participants. Am J Obstet Gynecol. 2021;224(6):629\u201331.","journal-title":"Am J Obstet Gynecol"},{"key":"4777_CR6","doi-asserted-by":"publisher","first-page":"100105","DOI":"10.1016\/j.eurox.2019.100105","volume":"5","author":"CR Dean","year":"2020","unstructured":"Dean CR, Bruin CM, O\u2019Hara ME, Roseboom TJ, Leeflang MM, Spijker R, et al. The chance of recurrence of hyperemesis gravidarum: A systematic review. Eur J Obstet Gynecol Reprod Biol X. 2020;5:100105.","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"issue":"9","key":"4777_CR7","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/aogs.14197","volume":"100","author":"K Nijsten","year":"2021","unstructured":"Nijsten K, Dean C, van der Minnen LM, Bais JM, Ris-Stalpers C, van Eekelen R, et al. Recurrence, postponing pregnancy and termination rates after hyperemesis gravidarum: follow-up of the MOTHER study. Acta Obstet Gynecol Scand. 2021;100(9):1636\u201343.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"4777_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12884-017-1249-0","volume":"17","author":"K Heitmann","year":"2017","unstructured":"Heitmann K, Nordeng H, Havnen GC, Solheimsnes A, Holst L. The burden of nausea and vomiting during pregnancy: severe impacts on quality of life, daily life functioning and willingness to become pregnant again - results from a cross-sectional study. BMC Pregnancy Childbirth. 2017;17(1):75.","journal-title":"BMC Pregnancy Childbirth"},{"key":"4777_CR9","volume-title":"The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. Green-top Guideline No 69","author":"Royal College of Obstetricians & Gynaecologists","year":"2016","unstructured":"Royal College of Obstetricians & Gynaecologists. The Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum. Green-top Guideline No 69. 2016.https:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/green-top-guidelines\/gtg69-hyperemesis.pdf\u00a0Accessed 21 Feb 2022."},{"key":"4777_CR10","volume-title":"Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]","author":"\u00c5 Vikanes","year":"2014","unstructured":"Vikanes \u00c5, Trovik J, Tellum T, Lomsdal S, Steinsl\u00f8kken A, Nesheim BI. Emesis and hyperemesis gravidarum. In: Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]. 2014.\nhttps:\/\/www.legeforeningen.no\/foreningsledd\/fagmed\/norsk-gynekologisk-forening\/veiledere\/arkiv-utgatte-veiledere\/veileder-i-fodselshjelp-2014\/7.-emesis-og-hyperemesis-gravidarum\/ Accessed 21 Feb 2022."},{"key":"4777_CR11","volume-title":"Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]","author":"IMG H\u00e6re","year":"2008","unstructured":"H\u00e6re IMG, Steinbakk A, Vikanes \u00c5V, Vilming B. Hyperemesis gravidarum. In: Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]. 2008. https:\/\/www.legeforeningen.no\/contentassets\/04d0b3c134ac4b12aa1a03c3a2666585\/veileder-i-fodselshjelp-2008.pdf\u00a0Accessed 21 Feb 2022."},{"key":"4777_CR12","volume-title":"Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]","author":"ML Johnsrud","year":"1998","unstructured":"Johnsrud ML, Brobak H. Hyperemesis gravidarum. In: Norsk gynekologisk forening \u2013 Veileder i f\u00f8dselshjelp [Norwegian Society of Gynecology and Obstetrics - guidelines in obstetrics]. 1998. https:\/\/www.nb.no\/nbsok\/nb\/2a69d2ca4258928a8e29f822ceee4487?index=1#0\u00a0Accessed 21 Feb 2022."},{"key":"4777_CR13","first-page":"Cd010607","volume":"5","author":"RC Boelig","year":"2016","unstructured":"Boelig RC, Barton SJ, Saccone G, Kelly AJ, Edwards SJ, Berghella V. Interventions for treating hyperemesis gravidarum. Cochrane Database Syst Rev. 2016;5:Cd010607.","journal-title":"Cochrane Database Syst Rev"},{"key":"4777_CR14","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 189: nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):e15-e30.","DOI":"10.1097\/AOG.0000000000002456"},{"issue":"12","key":"4777_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jogc.2016.08.009","volume":"38","author":"K Campbell","year":"2016","unstructured":"Campbell K, Rowe H, Azzam H, Lane CA. The Management of Nausea and Vomiting of Pregnancy. J Obstetrics Gynaecol Canada\u202f: JOGC. 2016;38(12):1127\u201337.","journal-title":"J Obstetrics Gynaecol Canada : JOGC"},{"issue":"23","key":"4777_CR16","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1001\/jama.2018.18307","volume":"320","author":"KF Huybrechts","year":"2018","unstructured":"Huybrechts KF, Hernandez-Diaz S, Straub L, Gray KJ, Zhu Y, Patorno E, et al. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring. JAMA. 2018;320(23):2429\u201337.","journal-title":"JAMA"},{"issue":"13","key":"4777_CR17","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/bdr2.1705","volume":"112","author":"C Picot","year":"2020","unstructured":"Picot C, Berard A, Grenet G, Ripoche E, Cucherat M, Cottin J. Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis. Birth Defects Res. 2020;112(13):996\u20131013.","journal-title":"Birth Defects Res"},{"key":"4777_CR18","unstructured":"The European Medicines Agency\u2019s Committee on Medicinal Products for Human Use (CHMP). European Medicines Agency recommends changes to the use of metoclopramide. EMA\/13239\/2014 Corr. 1. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/metoclopramide-containing-medicines Accessed 21. Feb 2022."},{"key":"4777_CR19","volume-title":"The Norwegian Medicines Agency","author":"The Norwegian Medicines Agency","year":"2013","unstructured":"The Norwegian Medicines Agency. Nye anbefalinger ved bruk av metoklopramid (Afipran) [New recommendations for the use of metoclopramide (Afipran)]. In: The Norwegian Medicines Agency. 2013. https:\/\/legemiddelverket.no\/nyheter\/nye-anbefalinger-ved-bruk-av-metoklopramid-afipran\u00a0Accessed 21 Feb 2022."},{"issue":"9","key":"4777_CR20","doi-asserted-by":"publisher","first-page":"e0257584","DOI":"10.1371\/journal.pone.0257584","volume":"16","author":"L Sun","year":"2021","unstructured":"Sun L, Xi Y, Wen X, Zou W. Use of metoclopramide in the first trimester and risk of major congenital malformations: A systematic review and meta-analysis. PLoS ONE. 2021;16(9):e0257584.","journal-title":"PLoS ONE"},{"key":"4777_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/CLEP.S287892","volume":"13","author":"M van Gelder","year":"2021","unstructured":"van Gelder M, Nordeng H. Antiemetic Prescription Fills in Pregnancy: A Drug Utilization Study Among 762,437 Pregnancies in Norway. Clin Epidemiol. 2021;13:161\u201374.","journal-title":"Clin Epidemiol"},{"key":"4777_CR22","unstructured":"Delivery statistics. In: Medical Birth Registry of Norway. http:\/\/statistikkbank.fhi.no\/mfr\/ Accessed 03. Oct 2021"},{"issue":"2","key":"4777_CR23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/1536867X1501500208","volume":"15","author":"A Linden","year":"2015","unstructured":"Linden A. Conducting interrupted time-series analysis for single- and multiple-group comparisons. Stata Journal. 2015;15(2):480\u2013500.","journal-title":"Stata Journal"},{"issue":"10","key":"4777_CR24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/1471-0528.15662","volume":"126","author":"L Fiaschi","year":"2019","unstructured":"Fiaschi L, Nelson-Piercy C, Deb S, King R, Tata LJ. Clinical management of nausea and vomiting in pregnancy and hyperemesis gravidarum across primary and secondary care: a population-based study. BJOG. 2019;126(10):1201\u201311.","journal-title":"BJOG"},{"key":"4777_CR25","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0119","author":"M Nana","year":"2021","unstructured":"Nana M, Morgan H, Ahmed H, Williamson C. Hyperemesis gravidarum in the primary care setting: Cross-sectional study of general practitioners. BJGP Open. 2021. https:\/\/doi.org\/10.3399\/BJGPO.2021.0119.","journal-title":"BJGP Open"},{"issue":"1","key":"4777_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/02813432.2015.1132894","volume":"34","author":"K Heitmann","year":"2016","unstructured":"Heitmann K, Svendsen HC, Sporsheim IH, Holst L. Nausea in pregnancy: attitudes among pregnant women and general practitioners on treatment and pregnancy care. Scand J Prim Health Care. 2016;34(1):13\u201320.","journal-title":"Scand J Prim Health Care"},{"issue":"5","key":"4777_CR27","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-017-2407-z","volume":"74","author":"K Svendsen","year":"2018","unstructured":"Svendsen K, Wood M, Olsson E, Nordeng H. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase\u00ae. Eur J Clin Pharmacol. 2018;74(5):627\u201336.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"4777_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11845-007-0005-2","volume":"176","author":"M Beirne","year":"2007","unstructured":"Beirne M, Fenton J. Acute dystonic reaction secondary to prochlorperazine use in the treatment of hyperemesis gravidarum. Ir J Med Sci. 2007;176(1):53\u20134.","journal-title":"Ir J Med Sci"},{"key":"4777_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pediatrneurol.2020.01.013","volume":"106","author":"L Kirkpatrick","year":"2020","unstructured":"Kirkpatrick L, Sogawa Y, Cleves C. Acute Dystonic Reactions in Children Treated for Headache With Prochlorperazine or Metoclopramide. Pediatr Neurol. 2020;106:63\u20134.","journal-title":"Pediatr Neurol"},{"key":"4777_CR30","unstructured":"L\u00f8keland-Stai M. Induced abortion in Norway \u2013 fact sheet. In: Norwegian Registry of Pregnancy Termination 2020. https:\/\/www.fhi.no\/en\/hn\/health-registries\/registry-of-pregnancy-termination\/induced-abortion-in-norway\/ Accessed 21 Feb 2022."},{"issue":"6","key":"4777_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.contraception.2007.08.009","volume":"76","author":"B Poursharif","year":"2007","unstructured":"Poursharif B, Korst LM, Macgibbon KW, Fejzo MS, Romero R, Goodwin TM. Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum. Contraception. 2007;76(6):451\u20135.","journal-title":"Contraception"},{"key":"4777_CR32","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2147\/RMHP.S263579","volume":"13","author":"H Kim","year":"2020","unstructured":"Kim H, Suh HS. Effects of a Safety Letter on Metoclopramide Use in Korea: An Interrupted Time-Series Analysis. Risk Manag Healthc Policy. 2020;13:1335\u201341.","journal-title":"Risk Manag Healthc Policy"},{"issue":"6","key":"4777_CR33","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/ajg.2012.300","volume":"108","author":"ED Ehrenpreis","year":"2013","unstructured":"Ehrenpreis ED, Deepak P, Sifuentes H, Devi R, Du H, Leikin JB. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol. 2013;108(6):866\u201372.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-022-04777-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-022-04777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T08:10:40Z","timestamp":1654157440000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-022-04777-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4777"],"URL":"https:\/\/doi.org\/10.1186\/s12884-022-04777-x","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved as an internal control and quality study by the data protection officer at Haukeland University Hospital Institutional Review Board, who granted access to patient files for the study personnel (reference number 2012\/8379 for the 2002\u20132011 cohort and 2017\/1383 for the 2012\u20132019 cohort). The Norwegian Regional Ethical Committee South-East has approved waiver of individual patient consent (REK 2018\/2305). All data were anonymized. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. JT has participated in developing the national HG-treatment guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"464"}}